{"id":"gallium-68ga-edotreotide","rwe":[{"pmid":"33104320","year":"2006","title":"Edotreotide Gallium Ga-68.","finding":"","journal":"","studyType":"Clinical Study"}],"tags":[{"label":"Peptide","category":"modality"},{"label":"Somatostatin receptor type 2","category":"target"},{"label":"SSTR2","category":"gene"},{"label":"V09IX09","category":"atc"},{"label":"Active","category":"status"},{"label":"Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate","category":"indication"},{"label":"Uihc Pet Imaging","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Uihc Pet Imaging","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=gallium (68Ga) edotreotide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:30:42.784105+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:30:49.698745+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:30:42.857133+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=gallium (68Ga) edotreotide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:30:50.081767+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297340/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:50.787569+00:00"}},"allNames":"ga 68 dotatate","offLabel":[],"synonyms":["Ga 68 dotatate","gallium (68Ga) edotreotide","gallium Ga 68-edotreotide","Ga-68 DOTA0-Tyr3-octreotide","gallium dotatoc Ga 68","gallium dotatoc GA-68"],"timeline":[{"date":"2016-12-08","type":"positive","source":"DrugCentral","milestone":"EMA approval (Advanced Accelerator Applications)"},{"date":"2019-08-21","type":"positive","source":"DrugCentral","milestone":"FDA approval (Uihc Pet Imaging)"}],"aiSummary":"Ga 68 Dotatate, developed by UIHC PET IMAGING, is a small molecule targeting the Somatostatin receptor type 2. It is used for Positron Emission Tomography with Computed Tomography of the whole body, and was FDA approved in 2019. Ga 68 Dotatate is a commercial product with its ownership retained by UIHC PET IMAGING, and its exact commercial status is not specified. Key safety considerations include the standard precautions for PET imaging. It is used to treat conditions that express the Somatostatin receptor type 2.","approvals":[{"date":"2016-12-08","orphan":false,"company":"Advanced Accelerator Applications","regulator":"EMA"},{"date":"2019-08-21","orphan":true,"company":"UIHC PET IMAGING","regulator":"FDA"}],"brandName":"Ga 68 Dotatate","ecosystem":[{"indication":"Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Somatostatin receptor type 2","novelty":"Follow-on","targets":[{"gene":"SSTR2","source":"DrugCentral","target":"Somatostatin receptor type 2","protein":"Somatostatin receptor type 2"}],"modality":"Peptide","explanation":"","oneSentence":"","technicalDetail":"Ga 68 Dotatate is a small molecule radiopharmaceutical that selectively binds to the Somatostatin receptor type 2 through a high-affinity interaction, enabling specific targeting and imaging of tumors expressing this receptor."},"commercial":{"launchDate":"2019","revenueYear":2025,"_launchSource":"DrugCentral (FDA 2019-08-21, UIHC PET IMAGING)","annualRevenue":305,"revenueSource":"SEC 8-K Novartis (2024-10-29)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:47.291579","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5185","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=gallium%20%2868Ga%29%20edotreotide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=gallium (68Ga) edotreotide","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:39:19.617659","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:52.349067+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"iobenguane (123I)","drugSlug":"iobenguane-(123i)","fdaApproval":"2008-09-19","relationship":"same-class"},{"drugName":"iobenguane (131I)","drugSlug":"iobenguane-(131i)","fdaApproval":"1994-03-25","relationship":"same-class"},{"drugName":"fludeoxyglucose (18F)","drugSlug":"fludeoxyglucose-(18f)","fdaApproval":"1994-08-19","relationship":"same-class"},{"drugName":"fluorodopa (18F)","drugSlug":"fluorodopa-(18f)","fdaApproval":"2019-10-10","relationship":"same-class"},{"drugName":"sodium fluoride F-18","drugSlug":"sodium-fluoride-f-18","fdaApproval":"1972-02-24","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fluoroestradiol F 18","drugSlug":"fluoroestradiol-f-18","fdaApproval":"2020-05-20","relationship":"same-class"},{"drugName":"fluciclovine (18F)","drugSlug":"fluciclovine-(18f)","fdaApproval":"2016-05-27","relationship":"same-class"},{"drugName":"methionine","drugSlug":"methionine","fdaApproval":"","relationship":"same-class"},{"drugName":"gallium (68Ga) gozetotide","drugSlug":"gallium-(68ga)-gozetotide","fdaApproval":"2020-12-01","relationship":"same-class"},{"drugName":"copper dotatate Cu-64","drugSlug":"copper-dotatate-cu-64","fdaApproval":"2020-09-03","relationship":"same-class"}],"genericName":"gallium (68ga) edotreotide","indications":{"approved":[{"name":"Positron emission tomography with computed tomography of whole body using gallium (68-Ga) dotatate","source":"DrugCentral","snomedId":764693004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"iobenguane-(123i)","brandName":"iobenguane (123I)","genericName":"iobenguane (123I)","approvalYear":"2008","relationship":"same-class"},{"drugId":"iobenguane-(131i)","brandName":"iobenguane (131I)","genericName":"iobenguane (131I)","approvalYear":"1994","relationship":"same-class"},{"drugId":"fludeoxyglucose-(18f)","brandName":"fludeoxyglucose (18F)","genericName":"fludeoxyglucose (18F)","approvalYear":"1994","relationship":"same-class"},{"drugId":"fluorodopa-(18f)","brandName":"fluorodopa (18F)","genericName":"fluorodopa (18F)","approvalYear":"2019","relationship":"same-class"},{"drugId":"sodium-fluoride-f-18","brandName":"sodium fluoride F-18","genericName":"sodium fluoride F-18","approvalYear":"1972","relationship":"same-class"},{"drugId":"fluoroestradiol-f-18","brandName":"fluoroestradiol F 18","genericName":"fluoroestradiol F 18","approvalYear":"2020","relationship":"same-class"},{"drugId":"fluciclovine-(18f)","brandName":"fluciclovine (18F)","genericName":"fluciclovine (18F)","approvalYear":"2016","relationship":"same-class"},{"drugId":"methionine","brandName":"methionine","genericName":"methionine","approvalYear":"","relationship":"same-class"},{"drugId":"gallium-(68ga)-gozetotide","brandName":"gallium (68Ga) gozetotide","genericName":"gallium (68Ga) gozetotide","approvalYear":"2020","relationship":"same-class"},{"drugId":"copper-dotatate-cu-64","brandName":"copper dotatate Cu-64","genericName":"copper dotatate Cu-64","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":["Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation","Metastatic Prostate Neuroendocrine Carcinoma","Metastatic Prostate Small Cell Neuroendocrine Carcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":30,"completionDate":"2026-11-02"},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":["Digestive System Neuroendocrine Tumor","Unresectable Digestive System Neuroendocrine Neoplasm","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2"],"enrollment":15,"completionDate":"2027-09-30"},{"nctId":"NCT04040088","phase":"EARLY_PHASE1","title":"An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-23","conditions":["Ganglioneuroblastoma","Ganglioneuroma","Neuroblastoma"],"enrollment":20,"completionDate":"2026-07"},{"nctId":"NCT07150806","phase":"PHASE1,PHASE2","title":"RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","status":"RECRUITING","sponsor":"Joshua Palmer","startDate":"2025-11-12","conditions":["Recurrent Meningioma"],"enrollment":30,"completionDate":"2026-12-31"},{"nctId":"NCT04082520","phase":"PHASE2","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-04-14","conditions":["Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Recurrent Meningioma","Unresectable Meningioma"],"enrollment":41,"completionDate":"2031-01-06"},{"nctId":"NCT04529044","phase":"PHASE2","title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-01","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma"],"enrollment":10,"completionDate":"2026-12-20"},{"nctId":"NCT04609592","phase":"PHASE1","title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-03-17","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":10,"completionDate":"2027-09"},{"nctId":"NCT03448458","phase":"PHASE2","title":"Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-02-22","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma","Stage IV Prostate Cancer AJCC v7"],"enrollment":17,"completionDate":"2023-02-06"},{"nctId":"NCT03576040","phase":"","title":"Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2018-07-19","conditions":["Neuroendocrine Tumors"],"enrollment":120,"completionDate":"2023-07-06"},{"nctId":"NCT06091748","phase":"PHASE3","title":"Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-02-22","conditions":["Advanced Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":66,"completionDate":"2025-11-01"},{"nctId":"NCT06455358","phase":"PHASE1,PHASE2","title":"61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-02-05","conditions":["Neuroendocrine Tumors"],"enrollment":27,"completionDate":"2028-06"},{"nctId":"NCT03953131","phase":"PHASE1","title":"Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-10","conditions":["Meningioma"],"enrollment":13,"completionDate":"2023-08-30"},{"nctId":"NCT01869725","phase":"PHASE2","title":"Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2013-04-01","conditions":["Adult Medulloblastoma","Childhood Medulloblastoma","Neuroblastoma","Neuroendocrine Tumor","Somatostatinoma"],"enrollment":68,"completionDate":"2018-12-26"},{"nctId":"NCT01619865","phase":"PHASE1,PHASE2","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2012-02-21","conditions":["Neuroendocrine Tumors","Carcinoid Tumors","Neuroblastoma","Medulloblastoma"],"enrollment":223,"completionDate":"2017-08-27"},{"nctId":"NCT03001349","phase":"EARLY_PHASE1","title":"68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-05-16","conditions":["Meningioma","Metastatic Well Differentiated Neuroendocrine Neoplasm","Multiple Endocrine Neoplasia Type 1","Neuroendocrine Neoplasm","Somatostatin Positive Neoplastic Cells Present","Von Hippel-Lindau Syndrome"],"enrollment":4,"completionDate":"2021-02-05"},{"nctId":"NCT03197012","phase":"EARLY_PHASE1","title":"Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor","status":"COMPLETED","sponsor":"Thomas Hope","startDate":"2017-07-01","conditions":["Neuroendocrine Tumor"],"enrollment":10,"completionDate":"2019-05-31"},{"nctId":"NCT02134639","phase":"","title":"PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-09","conditions":["Neuroendocrine Tumors"],"enrollment":20,"completionDate":"2015-01"},{"nctId":"NCT02194452","phase":"NA","title":"Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2013-09","conditions":["Acoustic Schwannoma","Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Meningioma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Choroid Plexus Tumor","Adult Craniopharyngioma","Adult Diffuse Astrocytoma","Adult Ependymoblastoma","Adult Ependymoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Grade I Meningioma","Adult Grade II Meningioma","Adult Medulloblastoma","Adult Meningeal Hemangiopericytoma","Adult Mixed Glioma","Adult Myxopapillary Ependymoma","Adult Oligodendroglioma","Adult Papillary Meningioma","Adult Pilocytic Astrocytoma","Adult Pineal Gland Astrocytoma","Adult Pineoblastoma","Adult Pineocytoma","Adult Subependymal Giant Cell Astrocytoma","Adult Subependymoma","Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)","Childhood Choroid Plexus Tumor","Childhood Craniopharyngioma","Childhood Ependymoblastoma","Childhood Grade I Meningioma","Childhood Grade II Meningioma","Childhood Grade III Meningioma","Childhood High-grade Cerebellar Astrocytoma","Childhood High-grade Cerebral Astrocytoma","Childhood Infratentorial Ependymoma","Childhood Low-grade Cerebellar Astrocytoma","Childhood Low-grade Cerebral Astrocytoma","Childhood Medulloepithelioma","Childhood Supratentorial Ependymoma","Meningeal Melanocytoma","Newly Diagnosed Childhood Ependymoma","Recurrent Adult Brain Tumor","Recurrent Childhood Anaplastic Astrocytoma","Recurrent Childhood Anaplastic Oligoastrocytoma","Recurrent Childhood Anaplastic Oligodendroglioma","Recurrent Childhood Brain Stem Glioma","Recurrent Childhood Cerebellar Astrocytoma","Recurrent Childhood Cerebral Astrocytoma","Recurrent Childhood Diffuse Astrocytoma","Recurrent Childhood Ependymoma","Recurrent Childhood Fibrillary Astrocytoma","Recurrent Childhood Gemistocytic Astrocytoma","Recurrent Childhood Giant Cell Glioblastoma","Recurrent Childhood Glioblastoma","Recurrent Childhood Gliomatosis Cerebri","Recurrent Childhood Gliosarcoma","Recurrent Childhood Medulloblastoma","Recurrent Childhood Oligoastrocytoma","Recurrent Childhood Oligodendroglioma","Recurrent Childhood Pilocytic Astrocytoma","Recurrent Childhood Pilomyxoid Astrocytoma","Recurrent Childhood Pineoblastoma","Recurrent Childhood Pleomorphic Xanthoastrocytoma","Recurrent Childhood Protoplasmic Astrocytoma","Recurrent Childhood Subependymal Giant Cell Astrocytoma","Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor","Recurrent Childhood Visual Pathway and Hypothalamic Glioma","Recurrent Childhood Visual Pathway Glioma","Untreated Childhood Anaplastic Astrocytoma","Untreated Childhood Anaplastic Oligodendroglioma","Untreated Childhood Brain Stem Glioma","Untreated Childhood Cerebellar Astrocytoma","Untreated Childhood Cerebral Astrocytoma","Untreated Childhood Diffuse Astrocytoma","Untreated Childhood Fibrillary Astrocytoma","Untreated Childhood Gemistocytic Astrocytoma","Untreated Childhood Giant Cell Glioblastoma","Untreated Childhood Glioblastoma","Untreated Childhood Gliomatosis Cerebri","Untreated Childhood Gliosarcoma","Untreated Childhood Medulloblastoma","Untreated Childhood Oligoastrocytoma","Untreated Childhood Oligodendroglioma","Untreated Childhood Pilocytic Astrocytoma","Untreated Childhood Pilomyxoid Astrocytoma","Untreated Childhood Pineoblastoma","Untreated Childhood Pleomorphic Xanthoastrocytoma","Untreated Childhood Protoplasmic Astrocytoma","Untreated Childhood Subependymal Giant Cell Astrocytoma","Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor","Untreated Childhood Visual Pathway and Hypothalamic Glioma","Untreated Childhood Visual Pathway Glioma"],"enrollment":0,"completionDate":"2017-03"}],"_emaApprovals":[{"date":"2016-12-08","status":"Authorised","company":"Advanced Accelerator Applications"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018100","RXNORM":"2199391","UMLSCUI":"C3640098","chemblId":"CHEMBL4297340","ChEMBL_ID":"CHEMBL4297340","KEGG_DRUG":"D11651","DRUGBANK_ID":"DB15494","PUBCHEM_CID":"71661158"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2019-","companyName":"Uihc Pet Imaging","relationship":"Original Developer"},{"period":"2016","companyName":"Advanced Accelerator Applications","relationship":"EMA Licensee"}],"publicationCount":1,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:47.31556+00","atcClassification":{"source":"DrugCentral","atcCode":"V09IX09","allCodes":["V09IX09"]},"biosimilarFilings":[],"originalDeveloper":"Uihc Pet Imaging","recentPublications":[{"date":"2006","pmid":"33104320","title":"Edotreotide Gallium Ga-68.","journal":""}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Uihc Pet Imaging","companyId":"uihc-pet-imaging","modality":"Peptide","firstApprovalDate":"2019","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-08-21T00:00:00.000Z","mah":"UIHC PET IMAGING","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:30:52.349067+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}